# Bladder Cancer

Bladder cancer is the clearest resistance-reversal setting for shikonin.

The reason is simple.

Cisplatin resistance is a major clinical problem, and the shikonin mechanism lines up closely with it.

### Why bladder cancer is a logical target

#### PKM2 rises in resistant cells

Cisplatin-resistant bladder-cancer cells show higher PKM2 expression than their cisplatin-sensitive parental lines.

That makes PKM2 part of the resistance phenotype, not just a background cancer marker.

#### Apoptosis is already impaired

Resistant bladder-cancer cells often have Bcl-2-related dysfunction that blocks normal apoptotic execution.

That is exactly where necroptosis becomes useful.

### The key mechanistic evidence

In T24 cisplatin-resistant bladder-cancer cells, shikonin induced cell death that could not be blocked by the broad caspase inhibitor z-VAD-fmk.

That argues against simple apoptosis.

The same death signal was blocked by necrostatin-1, a RIPK1 inhibitor.

That supports true necroptosis.

This is the most important point in the bladder-cancer literature.

Shikonin does not just add more stress to already resistant cells.

It re-opens a death route they had not blocked.

### PKM2 validation matters here

The case is stronger because it was not left as a pharmacology-only observation.

PKM2 knockdown by siRNA also restored cisplatin sensitivity.

That means the effect is much more likely to be target-relevant rather than random off-target toxicity.

### Tissue relevance

Human bladder-cancer tissue samples have shown higher PKM2 expression in tumour tissue than in normal tissue.

That does not prove clinical benefit.

It does support the relevance of the target in real disease.

### What remains unknown

* no immune-competent animal work
* no clinical trial data
* no established schedule beside cisplatin
* no subtype-specific mapping across muscle-invasive and non-muscle-invasive disease
* no human pharmacokinetic evidence showing the needed tissue exposure

### Bottom line

Bladder cancer offers the most mechanistically complete shikonin story in resistant disease.

PKM2 is elevated.

Shikonin inhibits it.

Necroptosis becomes accessible again.

That is why this page matters more than many loose “sensitisation” claims in natural-compound oncology.

### References

Li Z et al. (2018). PKM2 inhibitor shikonin overcomes cisplatin resistance in bladder cancer via necroptosis. *PMC / PLoS ONE.*\
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6231221/>

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/bladder-cancer.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.